Examination of homologies between Covid-19 vaccines and common allergens: the potential for T cell-mediated responses for allergic rhinitis and asthma.

Savannah Nicks, OMS-IV, Ben Greiner, DO, MPH, PGY-II, Micah Hartwell, PhD

INTRODUCTION
T-cell mediated antigen cross-reactivity between viruses and allergens is a relatively new area of study in clinical immunology; a discipline that may be particularly useful regarding the COVID-19 virus and the allergic response in humans. It has previously been demonstrated that the COVID-19 virus shares protein sequences with common allergens like grass pollens, dust mites, and molds. Thus post-infection, COVID-19 oriented T-cells may provide a mediated immune response to these allergens. Similarly, vaccination against COVID-19 may play a role in protection against T-cell-mediated chronic inflammation in allergic disease.

OBJECTIVES
Our objective was to explore the potential overlap between the COVID-19 vaccines from Pfizer and Moderna and common allergens indexed through two known and reputable databases.

METHODS
Given the protective factor of COVID-19 vaccines against the virus and their mass distribution, our objective was to explore the potential overlap between the COVID-19 mRNA vaccines from Pfizer-BioNtech and Moderna and known allergens indexed through the University of Nebraska’s FARRP Allergen Protein Database (allergenonline.org) and the FASTA tool, using the BLOSUM 50 scoring matrix as previously published. Given the Codex Alimentarius Commission recommendation likelihood of cross-reactivity criteria, we reported allergens with 35% (or greater) similarity over segments of 80 amino acids (Criteria A) and those with short (8 or more amino acids) identical matches (Criteria B).

RESULTS
For the Pfizer vaccine, we identified 1 allergen meeting Criteria A, from pine nuts, and 6 that met Criterion B from Tufted Grass and Alternaria Alternata, the most common fungal allergen associated with asthma (Figure 1). For the Moderna vaccine, we found 7 allergens meeting Criteria A and 12 that met Criteria B. Allergens meeting Criteria A included Spreading Pellitory (grass), lipocalin from Guinea Pigs, ragweed, wheat endosperm, sesame, and dust mites. Allergens that met Criteria B were Kentucky Blue, Cat, and Timothy Grasses, and Penicillium Crustosum (mold; Figure 1). Both vaccines showed matching sequences (Criteria B) with perennial ryegrass (Table 1).

CONCLUSION
Considering the homologous overlap of known allergens and the COVID-19 vaccines, an altered T-cell mediated immune response may be observed in allergic asthma and allergic rhinitis reaction after vaccination.

SIGNIFICANCE OF FINDINGS
These results suggest that vaccination with the Pfizer-BioNtech and Moderna COVID-19 vaccines may contribute to T-cell cross-reactivity with allergens that impact allergic asthma and allergic rhinitis.

REFERENCES
1. Skevaki C, Hudeemann C, Matrosovich M, et al. Influenza-derived peptides cross-react with allergens and provide asthma protection. J Allergy Clin Immunol. 2018;142(3):804-814.
2. Shen ZT, Nguyen TT, Daniels KA, Welsh RM, Stern LJ. Disparate Epitopes Mediating Protective Heterologous Immunity to Unrelated Viruses Share Peptide–MHC Structural Features Recognized by Cross-Reactive T Cells. The Journal of Immunology. 2013;191(10):5139-5152.
3. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12(9):669-677.
4. Balz K, Kaulshik A, Chen M, et al. Homologies between SARS-CoV-2 and allergen proteins may direct T cell-mediated heterologous immune responses. Sci Rep. 2021;11(1):4792.
5. Abdelmoteleb M, Zhang C, Furey B, et al. Evaluating potential risks of food allergy of novel food sources based on comparison of proteins predicted from genomes and compared to www.AllergenOnline.org. Food Chem Toxicol. 2021;114:111888.
6. Saleh PM, Arbes SJ Jr, Sever M, et al. Exposure to Alternaria alternata in US homes is associated with asthma symptoms. J Allergy Clin Immunol. 2006;118(4):892-898.
Examination of homologies between COVID-19 vaccines and common allergens: the potential for T cell-mediated responses for allergic rhinitis and asthma.

Authors: Savannah Nicks, OMS-IV², Micah Hartwell, Ph.D.¹², Benjamin Greiner, D.O., M.P.H., PGY-II³

Affiliations:

1. Oklahoma State University Center for Health Sciences, Department of Psychiatry and Behavioral Sciences, Tulsa, Oklahoma
2. Oklahoma State University Center for Health Sciences, Office of Medical Student Research, Tulsa, Oklahoma
3. University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas

Corresponding Author: Savannah Nicks, Oklahoma State University Center for Health Sciences

Address: 1111 W 17th St., Tulsa, OK 74107, United States.

Email: savannah.nicks@okstate.edu  Phone: (918) 561-1844

Medical School: Oklahoma State College of Osteopathic Medicine, OMS-IV

Abstract Word Count: 231

Conflicts of interest/Declarations: Dr. Hartwell receives grant funding through the National Institutes for Justice and Health Resources Services Administration—unrelated to the present work.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Abstract

Introduction
Current evidence suggests SARS-CoV-2 virus shares protein sequences with common allergens like grass pollens, dust mites, and molds. Thus post-infection, COVID-19 sensitized T-cells may provide a mediated immune response to these allergens. Similarly, vaccination against COVID-19 may play a role in protection against T-cell-mediated chronic inflammation in allergic disease.

Methods
Our objective was to explore the potential overlap between the COVID-19 vaccines from Pfizer and Moderna and common allergens indexed through two known and reputable databases. We reported allergens with 35% (or greater) similarity over segments of 80 amino acids (Criteria A) and those with short (8 or more amino acids) identical matches (Criteria B).

Results
For the Pfizer vaccine, we identified 1 allergen that met Criteria A, from pine nuts, and 6 that met Criterion B - notably, Tufted Grass and Alternaria alternata, the most common fungal allergen associated with asthma. For the Moderna vaccine, we found 7 allergens meeting Criteria A and 12 that met Criteria B.

Discussion
Considering our findings of overlap between known allergens and the Pfizer and Moderna vaccines, an altered T-cell mediated immune response may be observed in persons with allergic asthma and allergic rhinitis after vaccination, with Pfizer or Moderna mRNA vaccines, against COVID-19. These results suggest that vaccination with the Pfizer-BioNtech and Moderna COVID-19 vaccines may contribute to T-cell cross-reactivity with allergens that may positively impact allergic asthma and allergic rhinitis.
Asthma medications in schools: A cross-sectional analysis of the Asthma Call Back Survey

Sadie Schiffmacher, B.S.1, Rachel Wilkins, B.S.,1 Ashton Gatewood, M.P.H.,1 Savannah Nickels, B.S.,1 Benjamin Greiner, D.O., M.P.H.,1 Micah Hartwell Ph.D.2,3

1.Oklahoma State University Center for Health Sciences, Office of Medical Student Research; 2.Oklahoma State University Center for Health Sciences, Department of Psychiatry and Behavioral Sciences; 3 University of Texas Medical Branch, Galveston, Department of Internal Medicine

INTRODUCTION

- Asthma is the most common childhood chronic disease in the United States, with over 7.1 million children currently diagnosed. Moreover, one-third of those diagnosed with asthma in the US are children.1,6
- Quality treatment of complex conditions, such as asthma, requires appropriate patient screening and education.1,3
- Long-term goals of asthma management include achieving symptom control, maintaining a normal activity level, and minimizing risk of asthma-related mortality, exacerbations, persistent airflow, and side-effects of treatment.1,3,5

RESEARCH QUESTION

- Our objective was to analyze the amount of children with asthma permitted to carry medications in school and to assess the prevalence of children with an asthma action plan in school.

METHODS

- Using the CDC’s 2017 & 2018 BRFSS Asthma Call Back Survey for children, we assessed the prevalence of children in school that are allowed to carry medication and if they had an asthma action plan.
- We included only children who were in school and were reported to currently have asthma, ranging in age from 0-17 in BRFSS defined age groups shown in Figure 2.
- We assessed if there was a difference in allowance of asthma medication in schools or having asthma action plans based on urbanicity (rural vs. metro area).

SIGNIFICANCE OF FINDINGS

- Improving asthma control status positively impacts school absenteeism, academic success, and quality of life. These factors are further elevated with increased levels of asthma control, school environmental conditions, and teacher knowledge of student’s condition.3
- Establishing relationships between schools, healthcare students, and physicians is essential for effective asthma management plan implementation, especially in the educational setting.3,7
- Implementing protocols for stock albuterol to be supplied in schools increases access to medication for children who are not permitted to carry it.8
- The Osteopathic Principles and Practices should guide an osteopathic physician’s asthma management plan through the understanding that the body is a unit of mind, body, and spirit; capable of self-regulation, self-healing, and self-maintenance once that unity is restored.

RESULTS

- Nearly 35% of students reported that they were not allowed to carry asthma medications (Figure 1a) and 58% did not have a written asthma action plan (Figure 1b).
- Reported urbanicity was not significantly associated with either medication access at school (P=.46) or having an action plan (P=.57).
- Further, nearly 51% of children ages 5 - 9 and 33% of children ages 10-14 were unable to carry medications at school (Figure 2).

CONCLUSION

- More than one-third of students were not permitted to carry asthma medications and nearly 3 out of 5 did not have a written asthma action plan.
- These findings indicate the need for both access to medication in schools in addition to written action plans to improve asthma management in school.

REFERENCES

1. Banda, E., Persky, V., Chisum G., Damitz, M., Williams, R., & Turyk, M. (2013). Exposure to home and school environment triggers and asthma morbidity in Chicago inner-city school children. Journal of Allergy and Clinical Immunology, 132, 1143-48, doi:10.1016/j.jaci.2013.09.024.
2. Best, L. G., O'Leary, R. A., O'Leary, M. A., & Yracheta, J. M. (2016). Humoral immune factors and asthma among American Indian children: a systems approach. J Asthma: An Official Journal of the Asthma and Allergy Foundation of America, 53(8), 827-42.
3. Global Initiative for Asthma (GINA) (2019). Global strategy for asthma management and prevention. Retrieved from https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
4. McClure, Natasha, et al. "Using Academic Community Partnerships to Improve Asthma Care in Elementary Schools with Limited School Nurse Services." The Journal of School Health, vol. 90, no. 2, Feb. 2020, pp. 158–61, doi:10.1111/josh.12859.
5. Meradith, S. (2001). Factors associated with asthma and environmental exposures among American Indian children in the Northwest, M.S. Thesis. University of Washington.
6. Sawicki, G. & Haver, K. (2018). Asthma in children younger than 12 years: Initial evaluation and diagnosis. Uptodate. https://www.uptodate.com/contents/asthma-in-children-younger-than-12-years-initial-evaluation-and-diagnosis
7. V olerman, Anna, et al. "Ensuring Access to Albuterol in Schools: From Policy to Implementation. An Official American College of Allergy, Asthma, and Immunology Program." The Journal of Allergy and Clinical Immunology, vol. 138, no. 3, Sept. 2016, pp. 711–23, doi:10.1016/j.jaci.2016.06.015.
8. Vollerman, A., et al. “Asthma Control Action School Medicine. Assessment and Quality of School Lung Health Programs.” The Journal of School Health, vol. 85, no. 10, Oct. 2015, pp. 656–671, doi:10.1111/josh.12516.
Asthma medications in schools:

A cross-sectional analysis of the Asthma Call Back Survey 2017-2018

Presenting Author: Sadie Schiffmacher, B.S., OMS-I

Authors: Sadie Schiffmacher, B.S., OMS-I³, Rachel Wilkins, B.S., OMS-I³, Ashton Gatewood, M.P.H., OMS-II³, Savannah Nicks, OMS-IV³, Benjamin Greiner, D.O., M.P.H.¹, Micah Hartwell, Ph.D.²

Affiliations:

1. University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas
2. Oklahoma State University Center for Health Sciences, Department of Psychiatry and Behavioral Sciences, Tulsa, Oklahoma
3. Oklahoma State University Center for Health Sciences, Office of Medical Student Research, Tulsa, Oklahoma

Purpose of Research: Asthma is the most common chronic disease affecting children in the United States.¹,⁵ Goals for asthma management include symptom control, ability to maintain a normal activity level, and minimizing adverse events.

Research Question: Our objective is to analyze the amount of children with asthma that are permitted to carry medications at school and without an asthma action plan.

Methods: In this study we analyzed the Center for Disease Control and Prevention’s Asthma Call Back Survey to assess the prevalence of children in school allowed to carry medication and with
asthma action plans. Using sampling weights provided, we estimated population prevalence by age group and urbanicity.

**Results:** Results showed that, overall, 34.8% of students reported that they were not allowed to carry asthma medications in school. Specifically, nearly 51% of children ages 5 - 9 and 33% of children ages 10-14 were reported not to be allowed to carry medications at school (Figure 2). Further, 58.2% of children did not have a written asthma action plan. Reported urbanity was not significantly associated with access to medication at school (P=.46) or having an asthma action plan (P=.57).

**Conclusions:** In our study, more than one-third of students were not permitted to carry asthma medications and nearly three-fifths did not have a written asthma action plan. Osteopathic Principles and Practices should guide asthma management. Therefore, we recommend partnerships between schools, healthcare students, and physicians to increase access to asthma action plans and medication in schools.
The Use of Osteopathic Manipulative Therapies for the Reduction of Prescribed Opiate Morphine Milligram Equivalents in Patients Receiving Treatment for Chronic Pain: A Retrospective Study

Allon Gillispie, D.O., PGY-II, Alex Perez, D.O. PGY-III, Gretchen Stroud, D.O.
Comanche County Memorial Hospital Family Medicine Residency, Lawton, OK

Results

Background

- As of November 2020, the prevalence of chronic pain was 20.4% in the United States. Of those, most patients with chronic pain are in rural areas. Many of these patients are on long-term opiate therapy to address their pain. Presently, there is limited data on multimodal pain management approaches that include osteopathic manipulative therapies.
- With the ongoing opiate epidemic in the United States, safe reduction in Morphine Milligram Equivalents in patients using multimodal techniques is becoming a greater priority.
- Osteopathic techniques exist to safely and effectively treat patients of all ages with a variety of ailments.

Methods

- A retrospective study of patients within a rural outpatient primary care setting who were receiving treatment for chronic pain between the dates of January 1, 2021 and July 31, 2021 were analyzed.
- 210 patients with a diagnosis of chronic pain were included in the analysis. 30 were actively receiving OMT; 180 were not.
- Patients who were actively receiving OMT were compared to those who were not.
- Patients “actively receiving OMT” were defined by having received at least one dedicated OMT treatment during the data period. Modalities included well-known OMT techniques only.
- The primary outcome being assessed was total average opiate MMEs prescribed per month.
- Patient age and total length of opiate therapy were documented.

Results

|                        | OMT (n=30) | No OMT (n=180) | P-value   |
|------------------------|------------|----------------|-----------|
| Average MMEs Prescribed| 7.18 (±14.42) | 23.09 (±32.24) | 0.006655^a |
| Average Age in years   | 49.47(17.05)  | 59.21(14.89)  | 0.001352^a |

^One Factor ANOVA

Conclusions

- Augmenting chronic pain regimens with OMT appears to lead to fewer MMEs to achieve adequate pain control.
- OMT is anecdotally safe and efficacious for treating a variety of chronic pain complaints.
- OMT could be a viable option in helping combat the opiate epidemic.
- Further prospective study involving the use of OMT in patients with chronic pain is warranted.
- IRB approval has been obtained to pursue ongoing research by offering and providing OMT to patients being managed for chronic pain.

Limitations

- While this was a retrospective analysis of patients, ongoing prospective study is recommended to show improvement in patient outcomes.
- Objective measures such as reduced MMEs do not provide a complete picture of pain management. Subjective measures such as pain perception have great importance but are hard to objectively measure.
- Accurate average length of time receiving opiates could not be obtained as the Oklahoma Bureau of Narcotics and Dangerous Drugs (OBNDD) only allows for records to be searched back to 4 years.
- It is unknown whether patients receiving OMT required fewer MMEs before or after OMT was added to their treatment regimen.
- It is unknown to what extent MME reduction was prioritized in both patient groups.
- There is limited published data on the efficacy of OMT for chronic pain.

Sources

- Centers for Disease Control and Prevention. (2021, March 17). Overview | Drug Overdose | CDC Injury Center. Retrieved November 11, 2021, from https://www.cdc.gov/drugoverdose/deaths/prescription/overview.html
- Hedrich, D., Alves, P., Farrell, M., Stöver, H., Møller, L., & Mayet, S. (2012). The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction, 107(3), 501–517. https://doi.org/10.1111/j.1360-0443.2011.03676.x
- Licciardone, J. C., & Gatchel, R. J. (2020). Osteopathic Medical Care With and Without Osteopathic Manipulative Treatment in Patients With Chronic Low Back Pain: A Pain Registry–Based Study. Journal of Osteopathic Medicine, 12(2), 64–71. https://doi.org/10.7556/joma.2020.016
- Licciardone, J. C., Schultz, M. J., & Amen, B. (2020). Osteopathic Manipulation in the Management of Chronic Pain: Current Perspectives. Journal of Pain Research, Volume 13, 1839–1847. https://doi.org/10.2147/jpr.s183170
The Use of Osteopathic Manipulative Therapies for the Reduction of Prescribed Opiate Morphine Milligram Equivalents in Patients Receiving Treatment for Chronic Pain: A Retrospective Study

Allon Gillispie, D.O. PGY-II

Authors: Allon Gillispie, D.O., PGY-II, Charles Perez, D.O., PGY-III, Gretchen Stroud, D.O.

Affiliation: Comanche County Memorial Hospital Family Medicine Residency, Lawton, OK

Study Objective: The objective of this study was to show that the use of Osteopathic Manipulative Therapies (OMT) would lead to overall reduction in required Morphine Milligram Equivalents (MMEs) for the management of chronic pain.

Methods: The study was retrospective study of patients within an outpatient primary care setting whose chronic pain regimens did or did not include the use of OMT. The assessed outcome was the total average MMEs the two patient populations required on a monthly basis. Consideration was placed on confounding variables such as the average age of the patients in both groups and the average length of time in years patients had been receiving opiates. The source of pain was considered with the exclusion of patients with the associated diagnoses of cancer, neoplasm, or malignancy related pain.

Results: 210 patients with a diagnosis of chronic pain were included in the analysis. 30 were actively receiving OMT; 180 were not. There was significant difference in average MMEs (p=0.007) with the average MMEs of those receiving OMT was 7.2 ± 14.4. Compared to those not receiving OMT, 23.1 (±32.2). There was significant difference in the average age (p=0.001) with the average age of those receiving OMT of 49.47 (±17.05) and those without OMT 59.21 (±14.89).

Conclusions: Augmenting chronic pain regimens with OMT appears to lead to fewer required MMEs. This makes OMT a viable component in a multimodal approach to pain management. Further prospective study of the addition of OMT to patients’ pain management regimens is warranted.